| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2737 | Iproclozide | Irreversible and nonselective Monoamine_oxidase_inhibitor>monoamine oxidase inhibitor (MAOI) |
|
| DCC2738 | Ips-02001 | Novel inhibitor of protein-protein interaction (PPI), targeting integrin αvβ3-osteopontin interface, blocking OC maturation from murine bone marrow-derived macrophages, as well as the resorptive function of OCs, impairing downstream signaling of integrin |
|
| DCC2739 | Ipsalazide | Sulfasalazine analog, releasing 5-aminosalicylic acid and a nontoxic carrier molecule in the gastrointestinal tract |
|
| DCC2740 | Iqs-01.01rs | Novel potent inverse agonist of the chemokine receptor CXCR4, preventing CXCL12-mediated chemotaxis and triggering apoptosis in a panel of 18 cell lines and primary cultures, with superior mobilizing properties in vivo |
|
| DCC2741 | Ir-1061 | NIR-II cyanine dye for cancer treatment and diagnosis |
|
| DCC2742 | Irak Inhibitor 3 | Novel interleukin-1 (IL-I) receptor-associated kinase (IRAK) modulator |
|
| DCC2743 | Irak3 Degrader 23 | Novel potent and selective degrader of IRAK3, inducing proteasome-dependent degradation of IRAK3 and showing both CRBN and IRAK3 binding for activity |
|
| DCC2744 | Irak4-in-13 | Novel Orally Efficacious IRAK4 Inhibitor, Targeting MyD88L265P Mutant Diffuse Large B Cell Lymphoma |
|
| DCC2745 | Irc-083864 | Novel inhibitor of CDC25 phosphatases, actively against human cancer cells |
|
| DCC2746 | ire1-in-vii | Inhibitor of IRE1 endoribonuclease activity, strongly inhibiting XBP-1 splicing in an in vivo model of acute endoplasmic reticulum stress. |
|
| DCC2747 | Irl-1620 | ET B receptor agonist, showing anti-apoptotic activity and protecting neural cells in rats with cerebral ischemia |
|
| DCC2748 | Isam-c032 | Novel potent hA2BAR antagonist (Ki = 3.66 nM) |
|
| DCC2749 | Isatin-o | Neutral BBB crossing reactivator for acetylcholinesterase inhibited by paraoxon, also acting as anticonvulsant |
|
| DCC2750 | Isbogrel | Selective thromboxane A2 (TXA2) synthase inhibitor |
|
| DCC2751 | Isir-005 | Natural Stabilizer of the 14-3-3/Gab2 Protein-Protein Interaction (PPI) Interface |
|
| DCC2752 | Iso-dehydrozingerone | Novel osteoclastogenesis inhibitor, preventing ovariectomy-induced osteoporosis in ddY mice |
|
| DCC2753 | Isofagomine | Iminosugar, binding selectively to N370S glucocerebrosidase and restoring its correct conformation and, consequently, enhancing its activity |
|
| DCC2754 | Isomazole | Potent inotropic agent, inhibiting both PDE3 and PDE4 |
|
| DCC2755 | Isomyristicin | Natural essential oil, showing activity against T. muris |
|
| DCC2756 | Isopedopeptin B | Natural antibacterial agent with cytotoxicity and hemolytic properties against a larger panel of Gram-negative bacteria |
|
| DCC2757 | Iso-ppads | P2X-purinoceptor antagonist |
|
| DCC2758 | Isowighteone | Natural genistein derivetive with antibacterial and antifungal activities |
|
| DCC2759 | Isoxaben | Inhibitor of the cellulose biosynthesis, inhibiting anisotropic cell expansion resulting in a severely swollen and stunted growth phenotype |
|
| DCC2760 | Isox-inact | Biological Active Reagents |
|
| DCC2761 | Isph Inhibitor 23.20-tpp | Novel prodrug of potent IspH inhibitor, killing clinical isolates of several multidrug-resistant bacteria, including those from the genera Acinetobacter, Pseudomonas, Klebsiella, Enterobacter, Vibrio, Shigella, Salmonella, Yersinia, Mycobacterium and Baci |
|
| DCC2762 | Isp-vt | Novel inhibitor of COX and neutrophil migration |
|
| DCC2763 | Isq-1 Hydrochloride | Distinct IKur blocker |
|
| DCC2764 | Ist-622 | Unique topoisomerase inhibitor, showing significant growth-inhibitory effects against large-cell lung cancer (Lu-116) and gastric adenocarcinoma (St-4) |
|
| DCC2765 | Isvy130 | Novel Potent and Selective A3 Antagonist |
|
| DCC2766 | Ite-atra | Novel degrader of CRABP proteins |
|
